66 results about "CCL2" patented technology

It has been discovered that cytokines, chemokines, and growth factors in urine are biomarkers indicative of urological disorders including interstitial cystitis / painful bladder syndrome and overactive bladder syndrome. Preferred chemokine biomarkers are CCL2, CCL4 (MIP-1β), CCL11, CXCL1 (GRO-α), sCD40L, IL-12p70 / p40, IL-5, sIL-2Rα, IL-6, IL-10, IL-8, and EGF. The concentration of one or more of these chemokines in an urine sample can be used to assist in the diagnosis of urological disorders. Methods for evaluating the effectiveness of treatments for urological disorders and for assessing the severity of urological disorders are also provided.

This disclosure relates to methods of selecting a subset of subjects having a hematological disorder and treating the selected group with a PI3K-delta inhibitor. In particular, the methods disclose evaluating levels of characteristic chemokine biomarkers, such as CCL2, CCL3, CCL4, CCL5, CXCL13, CCL17, CCL22, or TNF-alpha to select subjects that would have a greater chance of benefiting from treatment with a PI3K-delta inhibitor. The PI3K-delta inhibitors disclosed in this application are a type of quinazolinone-purinyl family of compounds.

The invention relates to the field of medical diagnostics. More specifically, the invention relates to methods to diagnose or screen for inflammatory conditions or disease, including auto-inflammatory disease and affective disorder, in a subject, preferably a human subject, by assaying for a marker for an inflammatory disease. Provided is a method to diagnose, screen for or predict the development of an affective disorder (AD), preferably bipolar disorder (BP), in a subject, the method comprising determining the level of at least one, preferably at least two, more preferably at least three, most preferred at least four, AD-specific gene product(s) in a biological sample isolated from the subject, preferably peripheral blood monocytes, wherein the gene is selected from the group comprising ATF3, phosphodiesterase 4 B, CXCL2, BCL2-related protein A2, Dual specificity phosphatase 2, TNFα-induced protein 3 / A20, BTEB1 CXCL3, Chemokine CCL-3 like, CCL-4, CCL20, CX2CR1, Amphiregulin, Thrombomodulin, Heparin-binding EGF-like growth factor, DNA-damaged inducible transcript, V28 chemokine-like receptor, TRAIL. MAPK6, B4BP4, PBEF1, Thrombospondin 1, MAFF, HSP70, CCL2, MCP-3, CCR2, CX3CR1, DOK1, HBB, G-gamma globin, THBD, PHLDA1, DTR and GNLY.

The invention provides a kit for detecting an Alzheimer autoantibody in serum. The kit comprises an antigen protein combination, the antigen protein combination contains at least four proteins, and the proteins are selected from RABPT5, RAGE, CRYAB, SRPK1, MAPT, MBP, PLP1, PTCD2, FRMD8, POMC, DNAJC8, CENTA2, HSP60, ADARB1, ASXL1, EDRK, GDF11, P21, CCL2, IL18, VEGF, LENG1 and MRPL34. The inventionfurther provides application of the limited antigen protein combination to preparation of a reagent for detection, diagnosis or risk prediction of Alzheimer, and methods for detection, diagnosis or risk prediction of Alzheimer.

Methods for testing candidate drugs for treatment of age-related macular degeneration are provided. Ccl2-deficient, and Ccr2-deficient mice are used to determine the effect of candidate drugs and treatments on development of age-related macular degeneration. Also provided is a Ccl2-deficient, Ccr2-deficient dual knockout mouse, which is a useful animal model for age-related macular degeneration.

The present invention provides, among other things, bi-specific molecules including, but not limited to, antibodies, fynomers, aptamers, fuproteins, and protein binding domains that bind both CCL2 and LOXL2 and uses thereof, in particular, for treatment of scleroderma and related fibrotic and / or inflammatory diseases, disorders and conditions. In some embodiments, the present invention further provides methods and compositions for treatment of scleroderma and related fibrotic and / or inflammatory diseases, disorders and conditions based on the combination of mono-specific anti-CCL2 and anti-LOXL2 molecules.

Methods for testing candidate drugs for treatment of age-related macular degeneration are provided. Ccl2-deficient, and Ccr2-deficient mice are used to determine the effect of candidate drugs and treatments on development of age-related macular degeneration. Also provided is a Ccl2-deficient, Ccr2-deficient dual knockout mouse, which is a useful animal model for age-related macular degeneration.

The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.

A conjugate protein comprising a GM-CSF or a fragment thereof and a truncated CCL2 is described. The conjugate protein has unexpected immune suppressive, anti-obesity and tumoricidal properties and is useful in a variety of therapeutic applications.

The invention provides a human serum CCL2 enzyme-linked immunosorbent assay kit as well as preparation and use methods thereof. The human serum CCL2 enzyme-linked immunosorbent assay kit comprises an enzyme-labeled reaction plate, a CCL2 standard product, biotin-labeled antihuman CCL2 antibodies and streptavidin-labeled horse radish peroxidase, wherein the enzyme-labeled reaction plate is coated with mouse-anti-human CCL2 monoclonal antibodies. The preparation method of the human serum CCL2 enzyme-linked immunosorbent assay kit comprises the steps of preparing the enzyme-labeled reaction plate, the CCL2 standard product, the biotin-labeled antihuman CCL2 antibodies and streptavidin-labeled horse radish peroxidase, wherein the enzyme-labeled reaction plate is coated with the mouse-anti-human CCL2 monoclonal antibodies. The use method of the human serum CCL2 enzyme-linked immunosorbent assay kit comprises the steps of adding samples, biotinylation antibodies and horse radish peroxidase, and carrying out color developing and terminating.

The invention discloses a novel use of a bisbibenzyl compound, in particular application of the bisbibenzyl compound shown as formula (I) or formula (II) in the specifications to preparation of medicaments for resisting inflammation and rheumatic arthritis or treating tumours caused by inflammation. The result of a study shows that the bisbibenzyl compound can be used for significantly inhibiting activities of an inflammatory factor interleukin-6(IL-6), monocyte chemoattractant protein (MCP-1), and a nuclear factor kB (NF-KB), and inhibiting gene expressions of inflammatory factors such as IL-6, interleukin-1b(1L-1b), NG-KB, a chemotactic factor (CCL2), cyclooxygenase 2(COX-2), intercellular adhesion molecule (Icam), a tumour necrosis factor (TNF) and the like, and presents an excellent anti-inflammatory effect; therefore, the bisbibenzyl compound is the medicament for resisting the inflammation and rheumatic arthritis or treating tumours caused by inflammation, has excellent development prospects and can be used as an essential component to prepare relevant oral preparations, injections and the like.

The invention discloses an application of a scoring system based on an immunogene pair in prediction of immunotherapy curative effect and prognosis of a non-small cell lung cancer patient. The scoring system disclosed by the invention is carried out based on the following four immune related gene pairs: CCL2 and VEGFA genes, CDK1 and CXCL9 genes, HLA-DOB and LCK genes, and IL-12A and TBX21 genes. The IRGP index (IRGPI) calculated based on an immune gene pair scoring system constructed by the invention is significantly related to the progression-free lifetime of a non-small cell lung cancer patient receiving anti-PD-1 immunotherapy. Therefore, the four immune-related gene pairs and the scoring system constructed according to the four immune-related gene pairs can be used for performing curative effect and prognosis prediction on the non-small cell lung cancer patient receiving anti-PD-1 immunotherapy.

Provided herein are methods of treating an IDH mutant cancer in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising an all-trans retinoic acid (ATRA). In some embodiments, the methods increase an NK-cell-mediated immune response and / or a T cell-mediated immune response to the cancer. In some embodiments, the cancer is a glioma or a chondrosarcoma. In some embodiments, the expression of one or more NKG2D ligands (e.g., ULBP1 and ULBP3) is increased in a tumor microenvironment of the cancer. In some embodiments, CCL2 production, the number of NK cells, and / or apoptosis of tumor cells is increased in a tumor microenvironment of the cancer. In some embodiments, the subject has an IDH1 mutation at arginine 132 or an IDH2 mutation at arginine 172. In some embodiments, method reduces growth of a tumor.

The invention discloses a biomarker for forecasting the new auxiliary chemotherapy curative effect of breast cancer and a fluorescence quantitative immune PCR kit. The biomarker is at least one of a CCL2 gene, a CCR1 gene, a CXCL10 gene, a CXCL11 gene and an IL2RG gene. The five genes of the biomarker are efficiently expressed in a pCR group; the IL2RG gene has an extremely obvious expression difference (P is less than 0.01) in the pCR group and the NpCR group, and the other four genes have an obvious expression difference (P is less than 0.05) in the pCR group and the NpCR group; the five genes are indicated to be biomarkers for forecasting the new auxiliary chemotherapy curative effect of the breast cancer, and the blindness of new auxiliary chemotherapy is avoided.

The invention discloses an application of a [1,2,4]triazolo[4,3-B]pyridazine derivative as shown in a formula (I) and a pharmaceutically acceptable salt or polymorphic substance thereof in preparationof anti-inflammatory factor storm drugs. According to the invention, the compounds can inhibit the expression and secretion of a variety of inflammatory factors by up-regulating let-7 expression, especially, expression and secretion of key factors IL-1RA, IL-1alpha, IL-1beta, IL-6, IL-10, IL-18, IL-22, IP-10, CCL2, GM-CSF, TNF-alpha and the like which form inflammatory factor storm, have good drug safety and strong inflammatory factor inhibition effect, and can be used as candidate drugs for resisting inflammatory factor storm.

A method of treating an inflammation in a subject thereof is provided. The method comprising administering to the subject a therapeutically effective amount of CCL2, thereby treating the inflammation. Also provided are pharmaceutical compositions and unit dosage forms which comprise CCL2 for the treatment of inflammation.

The invention relates to an engineered immune cell for combined expression of CCR2b. In particular, the engineered immune cells of the present invention are T cells or NK cells. The CAR molecule containing the NKG2D extracellular domain and the CCR2b are jointly expressed in the CAR-T cell, so that the sensitivity of the CAR-T cell to chemotactic factors such as CCL2, CCL7 and the like can be improved through the CCR2b, the CAR-T cell efficiently migrates to focuses such as colorectal cancer, ovarian cancer, pancreatic cancer and the like, and the treatment efficiency is improved; and meanwhile, various target antigens on the surfaces of cells such as colorectal cancer, ovarian cancer, pancreatic cancer and the like can be recognized through NKG2D CAR molecules, the risk that the curative effect is reduced due to tumor heterogeneity or target antigen loss is reduced, and the tumor treatment effect is improved.

The present invention aims to provide a novel undifferentiated state-control agent that maintains and / or improves an undifferentiated state of undifferentiated cells. CCL2 or a protein containing a functional domain thereof is used as the undifferentiated state-control agent. By culturing undifferentiated cells in the presence of the control agent, it is possible to maintain and / or improve an undifferentiated state of the undifferentiated cells. Examples of the undifferentiated cells include embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells). The origin of the cells is not particularly limited, and may be a human, mouse, or the like, for example.

Described herein are compositions, methods and / or kits for determining the likelihood of a pregnant subject delivering at term, or developing a disorder associated with pregnancy. These compositions, methods and / or kits feature the measurement of the chemotactic activity of peripheral leukocytes, the measurement of ccl2 mRNA expression or the measurement of Fp or Otr protein expression.

The present invention provides a method for predicting the treatment response to anti-cancer immunotherapy of a mammalian cancer patient, the method comprising: a) measuring the gene expression of at least 2 the following cancer promoting genes: PTGS2, VEGFA, CCL2, IL8, CXCL2, CXCL1, CSF3, IL6, IL1B and IL A in a sample obtained from the tumour of the patient; b) measuring the gene expression of at least 2 of the following cancer inhibitory genes: CXCL11, CXCL10, CXCL9, CCL5, TBX21, EOMES, CD8B, CD8A, PRF1, GZMB, GZMA, STAT1, IFNG, IL12B and IL12A in a sample obtained from the tumour of the patient; c) computing a ratio of the gene expression of said at least 2 cancer promoting genes and the gene expression of said at least 2 cancer inhibitory genes; and d) making a prediction of the treatment response and / or prognosis of the patient based on the gene expression ratio computed in step c). Also provided are related methods for stratifying patients and for treating patients, including with immune checkpoint blockade therapy.

The present invention relates to products and compositions containing (i) a chemotherapeutic agent and (ii) at least an active compound chosen from CCL2 inhibitors, CCR2 inhibitors, NF-κB inhibitors, PARP-1 inhibitors and ATM inhibitors, as a combined preparation for simultaneous, separate or sequential use for inhibiting tumor development caused by tumor cell senescence induced by said chemotherapeutic agent. The invention also refers to a method for monitoring the response to a chemotherapeutic agent of a patient suffering from a cancer, and to a method for predicting the tumor size evolution and / or the onset of metastasis in a patient suffering from a cancer.

The invention discloses a method used for evaluating an immunomodulatory effect of lactobacillus acidophilus and an application of the method, and belongs to the field of biotechnology. According to the method provided by the invention, a dynamic change situation of immunity-related differentially expressed genes is detected, wherein the differentially expressed genes include up-regulated immunity-related genes CCL2, CCL20, IL1 alpha, IL1 beta, IL6ST, IL8, PTX3 and TNFRSF9 and a down-regulated immunity-related gene CXCR4. Through the method, the immunomodulatory effect of the lactobacillus acidophilus can be evaluated only by detecting nine immunity-related genes, and quick detection can be realized by utilizing Real Time PCR, so that the time is greatly shortened and the deficiency of existing evaluation of the immunomodulatory effect of the lactobacillus acidophilus is overcome; and the method is well verified in a mouse test and a Caco-2 cell.

The invention relates to an application of a natural small molecular compound ginsenoside Rg1 serving as a CCL2-CCR2 signaling pathway inhibitor and an application serving as a central anti-inflammatory drug. The ginsenoside Rg1 provided by the invention is safe and effective, can be used as a drug for treating and preventing nervous system diseases related to central inflammation, and can also be used as a health care product and a tool drug for researching a CCL2-CCR2 signaling pathway.

The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.

The invention discloses a construction method of animal and cell models for improving rosacea inflammation by artemisinin, and relates to the technical field of skin disease medicaments, in particularto a construction method of animal and cell models for improving rosacea inflammation by artemisinin. The method comprises the following steps of: (1) constructing an animal model for improving rosacea inflammation phenotype by artemisinin; and (2) constructing a cell model for improving rosacea inflammatory phenotype by artemisinin. The invention has the advantages that a potential new drug (artemisinin) for treating rosacea is discovered; the pathogenesis of the rosacea is explored; it is found that artemisinin can obviously improve LL37-induced rosacea-like inflammatory mouse skin lesion erythema, histopathological changes and increase of IL-1 beta, IL-6, TNF alpha and TLR2; meanwhile, artemisinin can reduce infiltration of skin lesion CD4 + T cells, macrophages and neutrophils and inhibit expression of immune cell related chemokines (CXCL10, CCL20, CCL2 and CXCL2) in skin lesion.

The invention relates to a detection primer group, a polymerase chain reaction (PCR) detection chip and a detection method for analyzing atherosclerosis related gene expression conditions of human beings and machin. The general atherosclerosis detection primer group for persons and machin comprises amplification primer pairs for respectively amplifying atherosclerosis related genes ACE, APOA1, APOC1, APOF, CCL2, CD40LG, DBP, EDN1, FAS, FASLG, FGG, GLG1, GRN, ICAM1, IL18, IL1beta, IL1RN, IL6, IL6ST, IL8, ITGalpha2beta, ITGalpha4, ITGalpha6, ITGalphaM, ITGalphaV, ITGbeta1, ITGbeta2, LTA, LTB, MTHFR, NFKbeta1, OLR1, PLAUR, PLTP, PON2, SELL, SELP, SELPG, SERPINE1, TIMP1, TNF and TNFRSF1B, and the sequences of the amplification primer pairs are nucleotide sequences shown as SEQ ID NO:1-84. The invention also provides the PCR detection chip containing the primer group and the detection method. The invention can accurately quantify and detect the expression condition of the atherosclerosis related genes of the persons and the machin, and has significance for promotion of basic research of atherosclerosis, prevention detection and clinical treatment.

The present invention concerns compositions and methods for inhibition of abnormal uterine bleeding (AUB), such as that associated with use of long-acting progestin-only contraceptives (LAPCs). An aspect of the invention concerns compositions comprising chemokine (C-C motif) ligand 2 (CCL2), or a biologically active fragment thereof, which may administered to subjects for inhibition of AUB. Another aspect of the invention concerns methods for inhibiting AUB, comprising administering an effective amount of CCL2, or a biologically active fragment thereof, to a subject in need thereof. Another aspect of the invention concerns a kit for inhibiting AUB.

The invention relates to a detection primer group, a polymerase chain reaction (PCR) detection chip and a detection method for analyzing atherosclerosis related gene expression conditions of human beings and machin. The general atherosclerosis detection primer group for persons and machin comprises amplification primer pairs for respectively amplifying atherosclerosis related genes ACE, APOA1, APOC1, APOF, CCL2, CD40LG, DBP, EDN1, FAS, FASLG, FGG, GLG1, GRN, ICAM1, IL18, IL1beta, IL1RN, IL6, IL6ST, IL8, ITGalpha2beta, ITGalpha4, ITGalpha6, ITGalphaM, ITGalphaV, ITGbeta1, ITGbeta2, LTA, LTB, MTHFR, NFKbeta1, OLR1, PLAUR, PLTP, PON2, SELL, SELP, SELPG, SERPINE1, TIMP1, TNF and TNFRSF1B, and the sequences of the amplification primer pairs are nucleotide sequences shown as SEQ ID NO:1-84. The invention also provides the PCR detection chip containing the primer group and the detection method. The invention can accurately quantify and detect the expression condition of the atherosclerosis related genes of the persons and the machin, and has significance for promotion of basic research of atherosclerosis, prevention detection and clinical treatment.

The present invention provides a method for predicting the treatment response to anti-cancer immunotherapy of a mammalian cancer patient, the method comprising: a) measuring the gene expression of atleast 2 the following cancer promoting genes: PTGS2, VEGFA, CCL2, IL8, CXCL2, CXCL1, CSF3, IL6, IL1B and IL1A in a sample obtained from the tumour of the patient; b)measuring the gene expression of atleast 2 of the following cancer inhibitory genes: CXCL11, CXCL10, CXCL9, CCL5, TBX21, EOMES, CD8B, CD8A, PRF1, GZMB, GZMA, STAT1, IFNG, IL12B and IL12A in a sample obtained fromthetumour of the patient; c) computing a ratio of the gene expression of said at least 2 cancer promoting genes and the gene expression of said at least 2 cancer inhibitory genes; and d) making a prediction of the treatment response and / or prognosis of the patient based on the gene expression ratio computed in step c). Also provided are related methods for stratifying patients and for treating patients, including withimmune checkpoint blockade therapy.

The invention discloses an application of a scoring system based on immune gene pairs in predicting the curative effect and prognosis of immunotherapy for patients with non-small cell lung cancer. The scoring system disclosed in the present invention is based on the following four immune-related gene pairs: CCL2 and VEGFA gene, CDK1 and CXCL9 gene, HLA-DOB and LCK gene, IL-12A and TBX21 gene. The IRGP index (IRGPI) calculated based on the immune gene pair scoring system constructed in the present invention is significantly correlated with the progression-free survival of non-small cell lung cancer patients receiving anti-PD‑1 immunotherapy. It shows that using the 4 immune-related gene pairs of the present invention and the scoring system constructed based on these 4 immune-related gene pairs can predict the curative effect and prognosis of non-small cell lung cancer patients receiving anti-PD-1 immunotherapy.